Discordance across several methods for drug susceptibility testing of drug-resistant mycobacterium tuberculosis isolates in a single laboratory

Journal of Clinical Microbiology

Volumn 52, Issue 1, 2014, Pages 156-163

  Banu, Sayera ^a   Rahman, S M Mazidur ^a   Khan, M Siddiqur Rahman ^a   Ferdous, Sara Sabrina ^a   Ahmed, Shahriar ^a   Gratz, Jean ^b   Stroup, Suzanne ^b   Pholwat, Suporn ^b   Heysell, Scott K ^b   Houpt, Eric R ^b  

^a INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; OFLOXACIN; RIFAMPICIN; STREPTOMYCIN;

ANALYTICAL EQUIPMENT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; GENOTYPE MTBDRPLUS LINE PROBE ASSAY; INTERMETHOD COMPARISON; KAPPA STATISTICS; L J PROPORTION METHOD; MGIT 960 SIRE AST METHOD; MYCOBACTERIOPHAGE QUANTITATIVE PCR BASED METHOD; MYCOBACTERIUM TUBERCULOSIS; MYCOTB MIC PLATE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUBERCULOSIS; XPERT MTB/RIF ASSAY;

ANTITUBERCULAR AGENTS; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; REPRODUCIBILITY OF RESULTS; TUBERCULOSIS;

EID: 84891507631     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02378-13     Document Type: Article

References (14)

1. WHO.1998. Guidelines for surveillance of drug resistance in tuberculosis. WHO and the International Union Against Tuberculosis and Lung Disease. Int. J. Tuberc. Lung Dis. 2:72-89.
2. Canetti G, Fox W, Khomenko A, Mahler HT, Menon NK, Mitchison DA, Rist N, Smelev NA. 1969. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull. World Health Organ. 41:21-43.
3. WHO. 2008. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB): Policy statement. WHO, Geneva, Switzerland.
4. WHO.2007. Use of liquid TB culture and drug susceptibility testing (DST) in low and medium income settings. Summary report of the Expert Group Meeting on the Use of Liquid Culture Media. WHO, Geneva, Switzerland.
5. Petroff SA. 1915. A new and rapid method for the isolation and cultivation of tubercle bacilli directly from the sputum and feces. J. Exp. Med. 21:38-42.
6. Pholwat S, Ehdaie B, Foongladda S, Kelly K, Houpt E. 2012. Real-time PCR using mycobacteriophage DNA for rapid phenotypic drug susceptibility results for Mycobacterium tuberculosis. J. Clin. Microbiol. 50:754-761. http://dx.doi.org/10.1128/JCM.01315-11.
7. Ardito F, Posteraro B, Sanguinetti M, Zanetti S, Fadda G. 2001. Evaluation of BACTEC Mycobacteria Growth Indicator Tube (MGIT 960) automated system for drug susceptibility testing of Mycobacterium tuberculosis. J. Clin. Microbiol. 39:4440-4444. http://dx.doi.org/10.1128/JCM .39.12.4440-4444.2001.
8. Hall L, Jude KP, Clark SL, Dionne K, Merson R, Boyer A, Parrish NM, Wengenack NL. 2012. Evaluation of the Sensititre MycoTB plate for susceptibility testing of the Mycobacterium tuberculosis complex against first-and second-line agents. J. Clin. Microbiol. 50:3732-3734. http://dx.doi.org/10.1128/JCM.02048- 12.
9. Kruuner A, Yates MD, Drobniewski FA. 2006. Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first-and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J. Clin. Microbiol. 44:811-818. http://dx.doi.org/ 10.1128/JCM.44.3.811-818.2006.
10. American Thoracic Society, CDC, Infectious Diseases Society of America. 2003. Treatment of tuberculosis. MMWR Recomm. Rep. 52(RR-11): 1-77. http://www.cdc.gov/mmwr/pdf/rr/rr5211.pdf.
11. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, Becerra MC, Benedetti A, Burgos M, Centis R, Chan ED, Chiang CY, Cox H, D'Ambrosio L, DeRiemer K, Dung NH, Enarson D, Falzon D, Flanagan K, Flood J, Garcia-Garcia ML, Gandhi N, Granich RM, Hollm-Delgado MG, Holtz TH, Iseman MD, Jarlsberg LG, Keshavjee S, Kim HR, Koh WJ, Lancaster J, Lange C, de Lange WC, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Mishustin SP, Mitnick CD, Narita M, O'Riordan P, Pai M, Palmero D, Park SK, Pasvol G, Pena J, Perez-Guzman C, Quelapio MI, Ponce-de-Leon A, Riekstina V, Robert J, Royce S, Schaaf HS, Seung KJ, Shah L, Shim TS, Shin SS, Shiraishi Y, Sifuentes-Osornio J, Sotgiu G, Strand MJ, Tabarsi P, Tupasi TE, van Altena R, Van der Walt M, Van der Werf TS, Vargas MH, Viiklepp P, Westenhouse J, Yew WW, Yim JJ. 2012. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: An individual patient data meta-analysis of 9,153 patients. PLoS Med. 9(8):e1001300. http://dx.doi.org/10. 1371/journal.pmed.1001300.
12. WHO. 2011. Guidelines for the programmatic management of drugresistant tuberculosis: 2011 update. WHO, Geneva, Switzerland.
13. Chigutsa E, Meredith S, Wiesner L, Padayatchi N, Harding J, Moodley P, Mac Kenzie WR, Weiner M, McIlleron H, Kirkpatrick CM. 2012. Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis. Antimicrob. Agents Chemother. 56:3857-3863. http://dx.doi.org/10.1128/AAC.00048-12.
14. Peloquin CA, Hadad DJ, Molino LP, Palaci M, Boom WH, Dietze R, Johnson JL. 2008. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob. Agents Chemother. 52:852-857. http://dx.doi.org/10.1128/AAC .01036-07.